Reshape Lifesciences Stock Shares Owned By Insiders
| RSLS Stock | USD 2.44 0.05 2.01% |
Fundamental analysis of ReShape Lifesciences allows traders to better anticipate movements in ReShape Lifesciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
ReShape | Shares Owned By Insiders | Build AI portfolio with ReShape Stock |
ReShape Lifesciences Company Shares Owned By Insiders Analysis
ReShape Lifesciences' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current ReShape Lifesciences Shares Owned By Insiders | 10.62 % |
Most of ReShape Lifesciences' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ReShape Lifesciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ReShape Shares Owned By Insiders Driver Correlations
Understanding the fundamental principles of building solid financial models for ReShape Lifesciences is extremely important. It helps to project a fair market value of ReShape Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since ReShape Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ReShape Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ReShape Lifesciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 10.62% of ReShape Lifesciences are shares owned by insiders. This is 30.04% lower than that of the Health Care Equipment & Supplies sector and 31.7% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 5.25% lower than that of the firm.
ReShape Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ReShape Lifesciences' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ReShape Lifesciences could also be used in its relative valuation, which is a method of valuing ReShape Lifesciences by comparing valuation metrics of similar companies.ReShape Lifesciences is currently under evaluation in shares owned by insiders category among its peers.
ReShape Lifesciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of ReShape Lifesciences from analyzing ReShape Lifesciences' financial statements. These drivers represent accounts that assess ReShape Lifesciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ReShape Lifesciences' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 670.7M | 439.3M | 448.0M | 71.5M | 82.2M | 78.1M | |
| Enterprise Value | 668.5M | 436.8M | 425.5M | 67.8M | 78.0M | 74.1M |
ReShape Lifesciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ReShape Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ReShape Lifesciences' managers, analysts, and investors.Environmental | Governance | Social |
ReShape Fundamentals
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.53 | ||||
| Profit Margin | (0.48) % | ||||
| Operating Margin | (1.65) % | ||||
| Current Valuation | 3.56 M | ||||
| Shares Outstanding | 2.39 M | ||||
| Shares Owned By Insiders | 10.62 % | ||||
| Shares Owned By Institutions | 0.72 % | ||||
| Number Of Shares Shorted | 185.34 K | ||||
| Price To Book | 4.83 X | ||||
| Price To Sales | 0.83 X | ||||
| Revenue | 8.01 M | ||||
| Gross Profit | 4.57 M | ||||
| EBITDA | (6.67 M) | ||||
| Net Income | (7.13 M) | ||||
| Cash And Equivalents | 11.49 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 967 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.12 X | ||||
| Book Value Per Share | 9.24 X | ||||
| Cash Flow From Operations | (4.43 M) | ||||
| Short Ratio | 0.50 X | ||||
| Earnings Per Share | 264.12 X | ||||
| Price To Earnings To Growth | (12.12) X | ||||
| Target Price | 1.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.81 | ||||
| Market Capitalization | 5.94 M | ||||
| Total Asset | 4.79 M | ||||
| Retained Earnings | (642.7 M) | ||||
| Working Capital | (397 K) | ||||
| Net Asset | 4.79 M |
About ReShape Lifesciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ReShape Lifesciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ReShape Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ReShape Lifesciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ReShape Stock Analysis
When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.